{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-unidentified-cause/prescribing-information/proton-pump-inhibitors-ppis/","result":{"pageContext":{"chapter":{"id":"2978bf31-384a-5964-bba7-5ca72e2a700a","slug":"proton-pump-inhibitors-ppis","fullItemName":"Proton pump inhibitors (PPIs)","depth":2,"htmlHeader":"<!-- begin field b99785a0-c410-4456-9013-61d31e35473f --><h2>Proton pump inhibitors (PPIs)</h2><!-- end field b99785a0-c410-4456-9013-61d31e35473f -->","summary":"","htmlStringContent":"<!-- begin item 81beb282-d5a7-4478-8d17-0600c8098b85 --><!-- end item 81beb282-d5a7-4478-8d17-0600c8098b85 -->","topic":{"id":"f89632d0-8e52-59da-bd63-555a73aa134f","topicId":"ac596995-c452-4bf5-81bf-0aea66eca309","topicName":"Dyspepsia - unidentified cause","slug":"dyspepsia-unidentified-cause","lastRevised":"Last revised in October 2018","chapters":[{"id":"9fdd530d-f12b-5642-954b-6284524a3fdb","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"4ac2b712-5571-56ca-9ac4-25c9e354a821","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"16fcbe75-c057-5b25-8039-9145eb897f12","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"be6e1eb9-7eb4-54b8-980d-7a18a90127c3","slug":"changes","fullItemName":"Changes"},{"id":"8eb7dbc2-40da-5433-b290-44902a364d61","slug":"update","fullItemName":"Update"}]},{"id":"a44ffd66-34ee-565e-8b89-d09f62dd9656","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ad917944-2a8c-561c-ba7d-5e5c7ea860e4","slug":"goals","fullItemName":"Goals"},{"id":"cbb4bad0-1dbe-5c62-9adc-bb1a65fe6381","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"54d592f8-f244-5cc8-aed5-81cb136af042","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4ca8a0b2-46c5-52c2-a05d-1ae84806cefd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c5e33c66-dee5-57d8-9eff-828ad855e204","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"eff9b41a-cac2-5b9a-8614-2486d8206ffd","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4dfc51d9-1416-5432-bc80-019f5708238c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ec8766af-6b0a-5a4d-8897-2e3ba2af658d","slug":"definition","fullItemName":"Definition"},{"id":"e1cbef45-8ac7-5376-a1d2-c5d0a2cc924b","slug":"causes","fullItemName":"Causes"},{"id":"c7487dda-a4e1-5d9e-bc96-e583302af12c","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"0eb82dd3-e433-5b8e-a8d9-46987aab8940","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d2acef31-cf6d-5e3e-b2e0-99bc02684183","slug":"assessment","fullItemName":"Assessment"},{"id":"86ebd63c-3596-5ac0-9cd3-4a312bb2d7e4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"f244ecd9-294a-5fa3-9b22-a2e8f2ae408c","fullItemName":"Management","slug":"management","subChapters":[{"id":"bafb1a12-7cf3-5c6c-921a-03d86efd995d","slug":"dyspepsia-unidentified-cause","fullItemName":"Scenario: Dyspepsia - unidentified cause"}]},{"id":"b50160d9-c6d3-5b75-a3a3-9a743c039fb4","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"2978bf31-384a-5964-bba7-5ca72e2a700a","slug":"proton-pump-inhibitors-ppis","fullItemName":"Proton pump inhibitors (PPIs)"},{"id":"a51b3918-0bed-5c45-887b-a5d3e5fd3031","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"8579e41d-876a-5f82-9cb8-04675dce1bb3","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"d41b619e-ef9e-59b6-876b-0b3d52f0884a","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"9ea259a4-6c7f-524f-8866-6164a9696c25","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"640d4b46-3f9c-5cef-aeda-9a374a03fae8","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"fe5b2b68-8d84-5867-bc39-c63cbcd815f8","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"0857fa25-e261-5ecd-b851-fbe52518072d","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"210b1a7b-a0e0-558a-acbe-539f538e840d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0e0cffca-8140-5660-bd87-d4288485522f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4726f06d-25b6-56d1-83c0-3d729c2bb571","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"301b4d9b-8d13-5cc1-8e9a-f8f68c4fa019","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5e963a22-e16a-5e4a-b7a9-072decaccaa1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d1d047d4-3011-5ca0-955c-b366ab2a9fb4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"cd5de0cc-ba55-5ad9-b09b-3025cc68334c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc0ebb19-4869-5b31-8bcf-f0b6e5af54db","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b50160d9-c6d3-5b75-a3a3-9a743c039fb4","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"24c4e712-1a66-566f-a22e-fe3151ffa9b7","slug":"choice-of-proton-pump-inhibitor","fullItemName":"Choice of proton pump inhibitor","depth":3,"htmlHeader":"<!-- begin field f1ab2f7e-7129-44b0-9ad2-c2b10df77d4c --><h3>Choice of proton pump inhibitor</h3><!-- end field f1ab2f7e-7129-44b0-9ad2-c2b10df77d4c -->","summary":"","htmlStringContent":"<!-- begin item 1affc86f-cfd5-42c2-abf8-e86b21f8bf48 --><!-- begin field 12a073bc-d367-4b69-9fb5-97dc9b53b9cc --><ul><li>Table 1 shows the recommended doses of proton pump inhibitors (PPIs) for the management of people with dyspepsia symptoms.</li></ul><p><strong>Table 1</strong><strong>. </strong>PPI doses for the management of people with dyspepsia symptoms.</p><table><thead><tr><th colspan=\"1\"><p>PPI</p></th><th colspan=\"1\"><p>Full or standard dose</p></th><th colspan=\"1\"><p>Low dose (on-demand dose)</p></th><th colspan=\"1\"><p>Double dose</p></th></tr></thead><tbody><tr><td colspan=\"1\">Omeprazole</td><td colspan=\"1\">20 mg once a day</td><td colspan=\"1\">* 10 mg once a day</td><td colspan=\"1\">40 mg once a day</td></tr><tr><td colspan=\"1\">Lansoprazole</td><td colspan=\"1\">30 mg once a day</td><td colspan=\"1\">15 mg once a day</td><td colspan=\"1\">* 30 mg twice a day</td></tr><tr><td colspan=\"1\">Pantoprazole</td><td colspan=\"1\">40 mg once a day</td><td colspan=\"1\">20 mg once a day</td><td colspan=\"1\">* 40 mg twice a day</td></tr><tr><td colspan=\"1\">Rabeprazole</td><td colspan=\"1\">20 mg once a day</td><td colspan=\"1\">10 mg once a day</td><td colspan=\"1\">* 20 mg twice a day</td></tr><tr><td colspan=\"1\">Esomeprazole</td><td colspan=\"1\">† 20 mg once a day</td><td colspan=\"1\">Not available</td><td colspan=\"1\">‡ 40 mg once a day</td></tr><tr><td colspan=\"4\">Doses should be given 30 minutes before breakfast and (if needed) 30 minutes before the evening meal, to provide optimal control of gastric pH.</td></tr><tr><td colspan=\"4\">* Off-label dose for GORD.</td></tr><tr><td colspan=\"4\">† This is lower than the licensed starting dose in GORD, but is considered to be dose-equivalent to other PPIs.</td></tr><tr><td colspan=\"4\">‡ This dose is recommended for double dose, because the 20 mg dose of esomeprazole is considered to be equivalent to omeprazole 20 mg.</td></tr><tr><td colspan=\"4\"><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">NICE, 2014</a>]</td></tr></tbody></table><!-- end field 12a073bc-d367-4b69-9fb5-97dc9b53b9cc --><!-- end item 1affc86f-cfd5-42c2-abf8-e86b21f8bf48 -->","subChapters":[]},{"id":"15a1b0dc-3ef5-5e40-a8b1-0e907525b3a1","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 15fd3f94-3b57-4f9f-b523-2bf7759f62d6 --><h3>Contraindications and cautions</h3><!-- end field 15fd3f94-3b57-4f9f-b523-2bf7759f62d6 -->","summary":"","htmlStringContent":"<!-- begin item 0bf227fe-c7d3-4bcc-97fe-42187a6e9e4f --><!-- begin field 36334d10-cfb4-4bce-b8b3-495b3c17861f --><ul><li><strong>Proton pump inhibitors (PPIs) should not be prescribed to people:</strong><ul><li>With alarm symptoms before endoscopy, as PPIs may mask the symptoms of upper gastrointestinal malignancy. If the person is already taking a PPI and subsequently needs an endoscopy, the PPI should be stopped at least 2 weeks before the procedure.</li></ul></li><li><strong>PPIs should be prescribed with caution to people:</strong><ul><li>At risk of osteoporosis — the person should maintain an adequate intake of calcium and vitamin D, and if necessary, be given additional bone-sparing therapy.</li><li>At risk of hypomagnesaemia — if possible, magnesium levels should be checked before starting PPI therapy and intermittently during long-term treatment, for example if the person is prescribed drugs that can cause hypomagnesaemia, such as digoxin and diuretics.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">MHRA, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">BNF 73, 2017</a>]</p><!-- end field 36334d10-cfb4-4bce-b8b3-495b3c17861f --><!-- end item 0bf227fe-c7d3-4bcc-97fe-42187a6e9e4f -->","subChapters":[]},{"id":"db48c676-0bc5-5d06-a88c-7354082b983a","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field be9492e9-9204-4eda-9277-9836079f4588 --><h3>Adverse effects</h3><!-- end field be9492e9-9204-4eda-9277-9836079f4588 -->","summary":"","htmlStringContent":"<!-- begin item 9db2f0b3-257e-46bd-8cf6-c31d13a691cd --><!-- begin field f0b8931f-19da-4c4b-aae6-38e57cec0623 --><p><strong>Adverse effects of proton pump inhibitors (PPIs) are usually mild and reversible.</strong></p><ul><li>Adverse effects include headache, diarrhoea, nausea, vomiting, abdominal pain, constipation, and dizziness.</li><li>Less common adverse effects include dry mouth, peripheral oedema, sleep disturbance, fatigue, paraesthesia, arthralgia, myalgia, pruritus, and rash.</li><li>Rare or very rare adverse effects include:<ul><li>Subacute cutaneous lupus erythematosus (SCLE), which can occur weeks, months, or years after exposure to a PPI. If suspected discontinue the PPI and seek specialist advice if needed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">MHRA, 2015</a>].</li><li>Taste disturbance, hepatitis, jaundice, depression, confusion, hallucinations, hyponatraemia, leucopenia, leucocytosis, pancytopenia, thrombocytopenia, visual disturbances, sweating, photophobia, and alopecia.</li></ul></li><li>Long-term PPI treatment may be associated with uncommon, serious adverse effects such as:<ul><li>Hypomagnesaemia — symptoms include muscle twitching, tremors, vomiting, fatigue, and loss of appetite. Case reports after one year of PPI therapy, but may occur after 3 months. This usually improves after magnesium replacement therapy and discontinuation of the PPI [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">MHRA, 2012</a>].</li><li>Increased risk of fractures — especially when used at high doses for over a year in the elderly [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">MHRA, 2012</a>].</li><li><em>Clostridium difficile </em>infection — due to the effect of decreasing gastric acidity.</li><li>Rebound acid hypersecretion syndrome — may occur after stopping long-term PPI therapy, although this may be more a theoretical risk than clinical phenomenon.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">NICE, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">BNF 73, 2017</a>]</p><!-- end field f0b8931f-19da-4c4b-aae6-38e57cec0623 --><!-- end item 9db2f0b3-257e-46bd-8cf6-c31d13a691cd -->","subChapters":[]},{"id":"e67d0e54-657a-5ba9-9eb6-f789dd0483c7","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 88767c8a-2670-4a45-a6df-83355e933cb1 --><h3>Drug interactions</h3><!-- end field 88767c8a-2670-4a45-a6df-83355e933cb1 -->","summary":"","htmlStringContent":"<!-- begin item 8d6afbf2-b69f-498d-8f1e-170ff78282f8 --><!-- begin field 3ad65061-3a9e-4a66-8014-1718acbfa7da --><p><strong>Possible drug interactions with proton pump inhibitors (PPIs) include:</strong></p><ul><li><strong>Digoxin </strong>— PPIs may cause a small rise in serum digoxin levels (although not considered clinically significant). The manufacturer of lansoprazole suggests that digoxin levels should be monitored if lansoprazole is started or stopped.</li><li><strong>Warfarin </strong>— PPIs can occasionally enhance the effects of warfarin. The<strong> </strong>international normalized ratio (INR) should be monitored in people taking warfarin if omeprazole, pantoprazole, or esomeprazole is started or stopped.</li><li><strong>Methotrexate </strong>— PPIs possibly reduce excretion of methotrexate, leading to an increased risk of methotrexate toxicity.</li><li><strong>Phenytoin </strong>— omeprazole and esomeprazole can occasionally enhance the effects of phenytoin.<strong> </strong>The manufacturers recommend that people taking phenytoin are carefully monitored if omeprazole or esomeprazole is started or stopped.</li><li><strong>Azole antifungals </strong>— the absorption of ketoconazole or itraconazole may be reduced during PPI treatment. Dose adjustment of the antifungal drug may be required during long-term PPI treatment.</li><li><strong>Clopidogrel </strong>— omeprazole and esomeprazole reduce the antiplatelet effect of clopidogrel, and concomitant use should be avoided. The other PPIs may also reduce the efficacy of clopidogrel, and this risk should be weighed against the potential benefit of the PPI [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">MHRA, 2010</a>].</li><li><strong>Protease inhibitors </strong>— PPIs can significantly affect plasma levels of some protease inhibitor drugs, including:<ul><li>Atazanavir — concurrent use of PPIs and atazanavir is not recommended as the absorption of atazanavir may be affected by a PPI (due to changes in gastric acidity). This may lead to a reduced plasma concentration of atazanavir which may affect its efficacy. If concurrent use is necessary, seek specialist advice.</li><li>Saquinavir — plasma concentration of saquinavir may be increased by PPI treatment, leading to increased risk of adverse effects.</li><li>Tipranavir — concurrent use with omeprazole or esomeprazole is not recommended, as tipranavir may reduce the plasma concentration of the PPI. If concurrent use is necessary, seek specialist advice.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">Baxter and Preston, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">BNF 73, 2017</a>]</p><!-- end field 3ad65061-3a9e-4a66-8014-1718acbfa7da --><!-- end item 8d6afbf2-b69f-498d-8f1e-170ff78282f8 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}